Hester Biosciences Ltd

The transcript does not explicitly mention the current or expected order book or pending orders for Hester Biosciences Limited. However, related insights include: - Nepal plant experiences volatile tender orders with no predictable pattern—orders can surge or fall unexpectedly. - African tenders are expected to grow with more countries likely to release tenders soon, although geopolitical issues have delayed some tenders. - The company is actively participating in government tender programs like the National Immunization Program, providing stable demand for certain vaccines (Goat Pox, PPR). - No grants are depended upon; the business relies mainly on tenders and growing private sector demand. - Supply visibility is improving with new facilities, like the BSL-3 and fill-finish facility expected to be capitalized by Q2/Q3 FY26. - The management prefers to provide clear projections post regulatory clearances for new vaccine-related order book insights. No concrete figures on order book or pending orders were provided.

- There is no concrete new capital expenditure (CAPEX) plan currently, mostly maintenance-related CAPEX only (Page 10). - The company generated around Rs. 70 Cr. cash from operations for FY25 and can manage current debt repayments from operations without needing new working capital (Page 10). - No explicit mention of plans for new debt or equity fundraising in the transcript. - The management focuses on efficient operations and debt reduction (debt reduced by Rs. 32 Cr. March '25 vs. March '24) (Page 10). - Overall, no immediate plans for fresh fundraising through debt or equity were indicated during the call.

- Current CAPEX plans are limited, primarily focused on maintenance. - The fill-finish facility is expected to be commercially utilized by Q2 or latest Q3 of FY'26. - The BSL-3 facility is awaiting administrative approval from BIRAC; commercialization timeline remains uncertain. - No concrete new CAPEX plans have been finalized at this time. - Strategic focus is on operational efficiency, strengthening profitability, and expanding international presence, especially in Africa and Asia. - Investment in distribution network expansion, including appointing marketing managers in African countries, is ongoing. - The new capacity (Rs. 176 crore capital work in progress) is being gradually utilized; expected to reach good production levels in about 3 years.

- FY'25 focused on improving operational efficiency and strengthening profitability, setting a solid foundation for future growth. - Divisional product sales grew 13% despite market headwinds; poultry vaccines and therapeutic products showing steady demand. - Expansion in Africa and parts of the Middle East and Central Asia is a key growth focus, with emphasis on building market presence. - Launch of Avian Influenza vaccine expected in FY'26 to be a significant growth driver. - Growth in Animal Health and Pet Care segments aimed to reduce dependence on poultry vaccines; health product segment is about 10 years old and expected to grow steadily. - Capacity expansion coming online by Q2-Q3 FY'26, with gradual utilization increase over three years. - Africa operations expected to breakeven in 1-2 years, with growing order pipeline and regional presence. - Focus on expanding preventive care, biosecurity products, and proprietary formulations to broaden market reach and sustainability.

- Hester Biosciences aims to strengthen profitability through continued operational improvements and cost management. - The company expects a growth trajectory in profits, with standalone profit up 17% in FY25 and consolidated profit up 36%. - Management is confident of returning to historical net margin levels of around 25% in the near future. - Expansion focus on Africa, Middle East, Central Asia, and Asia to drive revenue growth and achieve breakeven in Africa within 2 years. - Launch of new products, including the Avian Influenza vaccine by Q1 FY26, expected to be key growth drivers. - Emphasis on growing Animal Health and Pet Care divisions to diversify revenue streams beyond poultry vaccines. - With improved operational efficiency, inventory control, and higher-margin products, the company projects sustainable and profitable growth ahead.